Dr Michael Griffin – The Role of Transcription Factors in Chronic Adipose Tissue Inflammation

Jun 21, 2021 | Life Sciences & Biology, Medical & Health Sciences

A transcription factor known as Early B-Cell Factor 1 (EBF1) is key to the formation of fat cells, called adipocytes. Although it is also active in mature adipocytes, the function of EBF1 at this stage has been unclear. Dr Michael Griffin at Sam Houston State University in Texas is investigating how EBF1 is involved in the process of adipose tissue inflammation caused by obesity. This type of inflammation is believed to be the underlying cause of a multitude of diseases ranging from diabetes to cancer.

Obesity Worldwide

The World Health Organisation estimates that globally, around 40% of people are overweight and 13% are obese. Defined as having an excess of fat that can have adverse effects on health, an overweight or obese diagnosis is usually given after a person’s body mass index (BMI) is shown to be over 25 or over 30, respectively. BMI is calculated by dividing a person’s weight by the square of their height in meters (kg/m2). With prevalence in under 19s rising from 4% in 1975 to 18% in 2016, more deaths are now linked with being overweight than underweight worldwide.

Gaining excessive weight occurs when calories, or energy intake, is greater than energy expended. Commonly, this is down to too little physical activity and consuming fat-rich and sugary food and drinks, which are more readily available than they used to be. The modern age has introduced more sedentary jobs and easier access to transportation, both of which decrease a person’s calorie expenditure, and this may explain the rise in obesity levels.

Risks of Obesity

Being overweight can give rise to numerous health consequences – cardiovascular diseases, such as strokes, were the number one cause of death globally in 2012. Other risks include musculoskeletal disorders like osteoarthritis, numerous cancers like those of the liver, kidney and gallbladder, and in addition, type 2 diabetes mellitus.

There are two types of diabetes – type 1 diabetes is an autoimmune disorder, which causes your body to destroy the cells in the pancreas that make insulin. Type 2 diabetes is a condition that begins when, for any number of complex reasons, tissue cells like muscle and fat become resistant to the actions of insulin. Eventually, this wears out the pancreas, whereby it doesn’t make enough insulin, or it becomes ineffective. This form, generally caused by being overweight, accounts for 90% of all diabetes cases.

Normally, your pancreas produces and releases the insulin hormone in response to blood glucose (sugar) levels rising after eating and drinking. Insulin allows the glucose to enter cells to give them fuel for metabolic processes. However, if the insulin is not working properly, or your cells don’t respond to it, glucose in the blood will become dangerously elevated. More and more insulin will be released to try and combat this until eventually, the pancreas tires out and makes too little insulin, leading to a condition called hyperglycaemia. Without proper management, type 2 diabetes can gradually lead to damage throughout the body, with the potential to cause debilitating or even life-threatening ailments. Damage to the kidneys, eyes, feet, gums and other organs may all occur if blood sugar levels are not properly controlled.

Sufferers of type 2 diabetes may experience fatigue, unusual thirst, slow-healing injuries and blurred vision, but their symptoms tend to be easier to manage than those with type 1. A balanced diet and active lifestyle are great ways to combat type 2 diabetes as well as obesity, but medication and insulin injections can also be given.

EBF1 in Adipocyte Inflammation

Another potential consequence of obesity is fat cells (adipocytes) becoming inflamed. Inflammation is a natural immune response to harmful stimuli such as injury and infection, with the goal of protecting the body. Various chemicals, antibodies and proteins are released and sent to the affected site, in addition to increased blood flow. In healthy responses, inflammation is acute, meaning it is confined to the area of concern and dies down once the threat has passed. However, when this does not happen, perhaps because the trigger has not been resolved, inflammation can become chronic.

Chronic inflammation of adipose tissue may be an underlying cause of many of the health issues that can accompany obesity, such as tissue damage, insulin resistance, diabetes, cancer and others, because they often go hand-in-hand. In fact, it has been shown that people who are obese typically have two to three times more immune factors (small molecules involved in the immune and inflammatory response) in their blood plasma than what is considered normal. Adipocytes and the mechanisms by which inflammation occurs in them is the focus of Dr Michael Griffin’s research.

Based at Sam Houston State University in Texas, Dr Griffin and his team have gained novel insights into the biological pathways in adipocytes. He and his team determined that a promising target for investigation was a transcription factor called Early B-Cell Factor 1 (EBF1).

Transcription factors are proteins that control the first step of decoding the genome and making proteins that carry out the function of cells – transcription. Binding to a specific DNA sequence, they determine whether or not individual genes are allowed to be transcribed, which ensures the genes are expressed at the right time, place and amount. EBF1 was already known to be important in the formation of adipocytes, but very little information was available on why it can be found at high levels in mature cells and therefore which pathways it might regulate that lead to inflammation. To rectify this, the team set out to investigate the function of EBF1 in mature adipocytes and its targets for regulation.

Investigating EBF1 Regulation and Function

The team utilised two techniques in their research – transcriptional profiling and genome location analysis. Transcriptional profiling, also known as expression profiling, measures the expression of genes in a cell. When a gene is expressed, it means that it has gone through transcription to produce a small RNA strand which will go on to code for a protein. Therefore, to find out which genes are being expressed in a specific cell, you can measure how much of their consequent RNA is present in it.

Dr Griffin used this technique in adipocytes that had had the genes coding for the EBF1 knocked out (removed), resulting in cells that were deficient in the transcription factor. This meant that they could decipher which genes it controls and normally allows to be expressed. They also used genome-wide location analysis to establish where the genes that code for EBF1 are found on the genome.

He identified around 35,000 places where EBF1 binds to DNA to aid gene regulation. A few thousand of these sites are specific to adipocytes, meaning they are not found in other types of cells. Most of the sites that EBF1 occupies are called enhancers, which are small sections of DNA that promote (increase the likelihood) of a particular gene being transcribed when a transcription factor is bound to it.

In addition to these findings, the team found that in cells that lacked EBF1, the signalling from multiple metabolic and inflammatory pathways was reduced, suggesting that the transcription factor directly regulates their components. Some of the processes affected included the PI3K/AKT pathway, which regulates the cell cycle and survival, the MAPK pathway, which reads external signals to elicit appropriate responses and, the STAT1 pathway, which is involved in the immune response.

In total, Dr Griffin observed that the expression of 600 genes was altered by knockout of EBF1 in mature adipocytes. Many of these genes encode important intermediates in various signalling pathways, interestingly, including ones involved in inflammatory responses. The team also noticed a reduction in glucose uptake into cells in response to insulin, as well as diminished lipogenesis (fat creation). Overall, they concluded that EBF1 in fat cells plays an important role in regulating inflammation and insulin signalling.

Digging Deeper

The results of Dr Griffin’s initial study have helped us to understand the role of EBF1 in adipocytes and how it utilises transcription regulation to alter a number of signalling pathways as well as inflammation.

Now, Dr Griffin wants to focus his attention on digging deeper into this topic and finding out how EBF1 regulates inflammatory signalling in adipocytes. He has uncovered novel protein-protein interactions between the EBF1 protein and another well-known inflammatory transcription factor. This means that inflammatory pathways that we are already aware of are likely to kick off EBF1’s role in inflammation of adipocytes. It also suggests that the development of drugs designed to block these interactions could one day represent a viable treatment for Type 2 diabetes associated with obesity.

Therapeutics for Multiple Diseases Associated with Obesity

There is substantial evidence that chronic inflammation of adipose tissue as a result of being overweight is likely to be the root cause of many subsequent diseases (diabetes, heart disease, cancer etc). If the mechanisms behind this inflammation can be fully understood, the development of therapeutics that combat multiple obesity-caused diseases at the same time, is possible.

Designing drugs that utilise this information, especially regarding EBF1, may be an exciting avenue to explore in the future. A healthy diet with a good amount of exercise is always beneficial for treating obesity. But taking into account knowledge of inflammation could aid the prescription of personalised diets and exercise regimes, to better the quality of support and care of those who experience obesity. Dr Griffin hopes that understanding the inflammation pathways regulated by EBF1 will aid in the development of future therapeutics with the potential to treat multiple illnesses at once.


Meet the researcher

Dr Michael Griffin

Department of Molecular and Cellular Biology   
Sam Houston State University College of Osteopathic Medicine
Conroe, TX

Dr Michael Griffin gained his Bachelor of Science in Nutrition Science from Pennsylvania State University in 1998. He then went on to the University of California at Berkeley, where he achieved a PhD in Biochemical and Molecular Nutrition. Having served in research, mentoring and teaching posts across the USA, Dr Griffin is now Assistant Professor of Biochemistry and Molecular Biology at Sam Houston State University College of Osteopathic Medicine in the Department of Molecular and Cellular Biology. This is also where he carries out his research into type 2 diabetes, which focusses on the role of inflammation of adipocytes (fat cells) in insulin resistance.


E: michael.griffin@shsu.edu

W: https://www.shsu.edu/academics/osteopathic-medicine/about/directory/michael-griffin.html


National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)

Sam Houston State University College of Osteopathic Medicine

Further Reading

F Zatterale, M Longo, J Naderi, et al., Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes, Frontiers in Physiology, 2020, 10, 1607.

MS Burhans, DK Hagman, JN Kuzma, et al., Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus, Comprehensive Physiology, 2018, 9, 1–58.

A Singh, MA Babyak, DK Nolan, et al., Gene by stress genome-wide interaction analysis and path analysis identify EBF1 as a cardiovascular and metabolic risk gene, European Journal of Human Genetics, 2015, 23, 854–862.

MJ Griffin, Y Zhou, S Kang, et al., Early B-cell Factor-1 (EBF1) is a Key Regulator of Metabolic and Inflammatory Signaling Pathways in Mature Adipocytes, Journal of Biological Chemistry, 2013, 288, 35925–35939.

Want to republish our articles?


We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence
(CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

More articles you may like

Dr Jerry Zhang | Cleansing Indoor Spaces with Ultraviolet Light

Dr Jerry Zhang | Cleansing Indoor Spaces with Ultraviolet Light

Maintaining air quality in indoor spaces like shopping centres, stadiums, and airports is a key issue in modern society. Unfortunately, current air conditioning-based approaches are often energy intensive and inefficient. A viable alternative is the use of low-energy-consumption ultraviolet light disinfection systems, which cleanse the air of bacteria and pathogens in indoor settings. Dr Jerry Zhang and his team of ultraviolet light-based disinfection technology specialists at Bolb Inc. have developed a model to predict device performance and lifetime under different conditions, providing crucial guidance for their adoption in large-scale settings.

Dr Jerry Zhang | Cleansing Indoor Spaces with Ultraviolet Light

Professor Petra Amann | Cataloguing and Analysing Etruscan Mirrors in Austrian Collections

The Etruscan people lived in the Apennine Peninsula in the 1st millennium BC, but their important classical legacy remains a fascinating topic to this day. Of particular interest and intrigue are the Etruscan mirrors – metal mirrors decorated with images and Etruscan inscriptions. Professor Petra Amann at the University of Vienna is working with colleagues to record and analyse all Etruscan mirrors held in public collections in Austria.

Dr Elif E. Miskioğlu – Dr Kaela M. Martin – Dr Adam R. Carberry | Intuition and Solving Complex Engineering Problems

Dr Elif E. Miskioğlu – Dr Kaela M. Martin – Dr Adam R. Carberry | Intuition and Solving Complex Engineering Problems

Experienced engineers are typically equipped with advanced technical knowledge and a unique skill set but also a marked intuition that allows them to come up with solutions to complex real-world problems. Drs Elif E. Miskioğlu, Kaela M. Martin, and Adam R. Carberry, at Bucknell University, Embry-Riddle Aeronautical University Prescott, and The Ohio State University, respectively, recently engaged in important research to support the understanding of intuition in engineering practice.

Dr Mark Sainsbury | Did David Hume Anticipate Daniel Kahneman’s View of the Mind?

Dr Mark Sainsbury | Did David Hume Anticipate Daniel Kahneman’s View of the Mind?

In his best-selling book Thinking, Fast and Slow (2011), Daniel Kahneman distinguishes between two systems of thought: System 1 involves fast, intuitive thinking, whereas System 2 is characterised as slow, reason-based thinking. More than two hundred years earlier, the philosopher, economist and historian David Hume made what Dr Mark Sainsbury (University of Texas at Austin) argues is a similar distinction. Like Kahneman, Hume proposed that much of our behaviour is determined in the first (fast) way rather than the second (slow) way. For both Hume and Kahneman, the upshot is that Reason plays a much less important role in our lives than is often thought.